Results 31 to 40 of about 63,898 (235)

Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview

Metabolites, 2023
Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co ...
Ahmed Ismail Eatmann, Esraa Hamouda, Heba Hamouda, Hossam Khaled Farouk, Afnan W. M. Jobran, Abdallah A. Omar, Alyaa Khaled Madeeh, Nada Mostafa Al-dardery, Salma Elnoamany, Eman Gamal Abd-Elnasser, Abdullah Muhammed Koraiem, Alhassan Ali Ahmed, Mohamed Abouzid, Marta Karaźniewicz-Łada   +13 more
doaj   +1 more source

Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]

, 2015
The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core   +3 more sources

Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation

Biochemistry and Biophysics Reports, 2021
Although thalidomide is highly teratogenic, it has been prescribed for treating multiple myeloma and Hansen's disease. However, its mechanism of action is not fully understood.
Maho Shimizu, Saoko Tachikawa, Nagatsuki Saitoh, Kohei Nakazono, Liu Yu-Jung, Mika Suga, Kiyoshi Ohnuma   +6 more
doaj  

Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma

Veterinary Sciences, 2020
Hemangiosarcomas (HSA) are common neoplasms of dogs that often metastasize and are typically fatal. Recently it was demonstrated that thalidomide extends the survival time of dogs with HSA, potentially due to thalidomide-induced inhibition of vascular ...
Jonathan P. Bray, John S. Munday
doaj   +1 more source

Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines [PDF]

Thalidomide is an immunomodulatory and anti-inflammatory agent and is used in autoimmune disorders. It has been shown that thalidomide inhibits proinflammatory cytokines production.
امیرشاهرخی, کیوان, قاضی خوانساری, محمود   +1 more
core   +1 more source

Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports

Revista da Sociedade Brasileira de Medicina Tropical, 2020
INTRODUCTION: Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL).
Pugazhenthan Thangaraju, Sajitha Venkatesan, Meenalotchini Gurunthalingam, Shoban Babu, Tamilselvan T   +4 more
doaj   +1 more source

Pancreatic cancer cachexia: a review of mechanisms and therapeutics. [PDF]

, 2014
Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge.
Andrew Eugene Hendifar, Andrew Eugene Hendifar, Carlyn Rose Tan, Laith eJamil, Nick eNissen, Patrick eYaffee, Richard eTuli, Simon eLo, Stephen J Pandol   +8 more
core   +2 more sources

The Use of Thalidomide in Steroid Dependent Continous Erythema Nodosum Leprosum Leprosy Patient: A Case Report

Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2016
Background: Treatment thalidomide in erythema nodosum leprosum (ENL), can inhibits the transcription repression mediated by tumor necroting factor (TNF). Thalidomide can be used as sparing agents drug to reduce the dependency of steroid.
Dian Pertiwi Habibie, M Yulianto Listiawan   +1 more
doaj   +1 more source

Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety

EBioMedicine, 2017
Trial Design: Open-label, randomised, controlled, pilot proof-of-concept clinical trial. Methods: Participants: Antiretroviral naïve adult males with CD4 count ≥350 cells/mm3. Interventions: Patients were randomised to receive thalidomide 200 mg QD for 3 
Tânia R.C. Vergara, Sadia Samer, Joanna R. Santos-Oliveira, Leila B. Giron, Muhammad Shoaib Arif, Maria Luciana Silva-Freitas, Lia A. Cherman, Mauro S. Treitsman, Alberto Chebabo, Maria Cecilia A. Sucupira, Alda M. Da-Cruz, Ricardo Sobhie Diaz   +11 more
doaj   +1 more source

Augmentation of Pectoral Fin Teratogenicity by Thalidomide in Human Cytochrome P450 3A-Expressing Zebrafish

Pharmaceuticals, 2023
The pharmacological and toxicological effects of active metabolites of enzymes including cytochrome P450 (CYP) are important. While it has been believed for a long time that thalidomide causes characteristic limb malformation only in rabbits and primates
Wenjing Dong, Ippo Akasaka, Akifumi Komiyama, Tatsuro Nakamura, Naohiro Mizoguchi, Tasuku Nawaji, Shinichi Ikushiro, Makoto Kobayashi, Hiroki Teraoka   +8 more
doaj   +1 more source